The relatively small Danish medical equipment company focused on diagnostics, Medical Prognosis Institute (MPI), could – if all goes well – be headed for the American market with two new products by the end of the year. The company’s core product, which has been under development for seven years, is a piece of diagnostic equipment aimed at cancer patients, a so-called Drug Response Predictor.
“With our diagnostic equipment we can predict which cancer patients will respond to, say, chemotherapy – that is, it can predict whether or not the patients’ tumor will disappear,” says company founder and Chief Research Officer Steen Knudsen. He is a former professor at the Danish Technical University, DTU, and has written several books about DNA Microarrays, also known as DNA-chips.
Mere fra MedWatch
Den internationale antibiotikaalliance Carb-X har fået tilsagn om yderligere 370 mio. dollar til at accelerere udviklingen af ny antibiotika og håndtere den stigende resistens over for lægemidler. Milliardindsprøjtningen vækker begejstring hos danske aktører, for som det er nu, fungerer markedet for antibiotika ikke, lyder det.